Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | THPO | P40225 | 1/20 | 0.36 |
| ▸ | STAT6 | P42226 | 1/20 | 0.36 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | BLM | P54132 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20581981 | 1.00 | MAPK1 (0.36) | MAPK1SMN1; SMN2TP53NFKB1CYP2C19 | |
| SCHEMBL22127645 | 1.00 | MAPK1 (0.36) | MAPK1SMN1; SMN2TP53NFKB1CYP2C19 | |
| SCHEMBL20054632 | 1.00 | MAPK1 (0.36) | MAPK1SMN1; SMN2TP53NFKB1CYP2C19 | |
| Fluoride SCHEMBL21933484 | 0.83 | MAPK1 (0.34) | MAPK1SMN1; SMN2TP53NFKB1CYP2C19 | |
| SCHEMBL20221108 | 0.82 | L3MBTL1 (0.33) | — | |
| Fluoride SCHEMBL23795544 | 0.82 | MAPK1 (0.33) | MAPK1SMN1; SMN2TP53NFKB1CYP2C19 | |
| Fluoride SCHEMBL22129962 | 0.82 | MAPK1 (0.33) | MAPK1SMN1; SMN2TP53NFKB1CYP2C19 | |
| Fluoride SCHEMBL23795550 | 0.82 | MAPK1 (0.33) | MAPK1SMN1; SMN2TP53NFKB1CYP2C19 | |
| SCHEMBL16796676 | 0.81 | MAPK1 (0.35) | MAPK1SMN1; SMN2TP53NFKB1CYP2C19 | |
| SCHEMBL22141637 | 0.79 | POLB (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3634430-B1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2024-06-06 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2023-11-14 | — | — | US | disclosed |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V INC (US) | 2023-09-21 | — | — | US | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-06-17 | — | — | US | disclosed |
| EP-3801496-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | Flagship Pioneering Innovations V, Inc. (US) | 2021-04-14 | — | — | EP | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2021-03-23 | — | — | US | disclosed |
| CN-112367987-A | Active agents and methods for their use in treating metabolic disorders and non-alcoholic fatty liver disease | 旗舰创业创新五公司 | 2021-02-12 | — | — | CN | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FLAGSHIP PIONEERING, INC. | 2020-06-25 | — | — | US | disclosed |
| EP-3634430-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | Flagship Pioneering Innovations V, Inc. (US) | 2020-04-15 | — | — | EP | disclosed |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | KINTAI THERAPEUTICS, INC. | 2020-04-02 | — | — | US | disclosed |
| CN-110869024-A | Multi-biological agents and methods of use thereof | 旗舰创业创新五公司 | 2020-03-06 | — | — | CN | disclosed |
| WO-2018226732-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2018-12-13 | — | — | WO | disclosed |
| EP-3019196-B1 | COMBINATIONS OF HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-06-06 | — | — | EP | disclosed |
| EP-2802326-B1 | HEPATITIS C VIRUS INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-04-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11813272-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | MAPK1 4177/4885SMN1; SMN2 4118/4885TP53 3924/4885 |
| US-20240180941-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | MAPK1 4177/4885SMN1; SMN2 4118/4885TP53 3924/4885 |
| US-20200101030-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | MAPK1 4462/4885SMN1; SMN2 2598/4885TP53 4391/4885 |
| US-20230293458-A1 | MULTIBIOTIC AGENTS AND METHODS OF USING THE SAME | SI, FABP2, CEL | MAPK1 4462/4885SMN1; SMN2 2598/4885TP53 4391/4885 |
| US-20200197428-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | MAPK1 4177/4885SMN1; SMN2 4118/4885TP53 3924/4885 |
| US-20210177877-A1 | ACTIVE AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF METABOLIC DISORDERS AND NONALCOHOLIC FATTY LIVER DISEASE | FABP1, PYGL, LIPC | MAPK1 4177/4885SMN1; SMN2 4118/4885TP53 3924/4885 |
| US-10953027-B2 | Active agents and methods of their use for the treatment of metabolic disorders and nonalcoholic fatty liver disease | FABP1, PYGL, LIPC | MAPK1 4177/4885SMN1; SMN2 4118/4885TP53 3924/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.